CD34 and acute myeloid leukemia: Interestingly, Yoshida et al. reported that Aurora B and Survivin in BM CD34+ cells were highly expressed in patients with high-risk MDS and secondary AML (arising from MDS), suggesting that dysregulation of the CPC was closely related to high-risk MDS (42).